PLx Pharma Inc.·4

Apr 20, 9:15 PM ET

PLx Pharma Inc. 4

4 · PLx Pharma Inc. · Filed Apr 20, 2017

Insider Transaction Report

Form 4
Period: 2017-04-19
Giordano Natasha
DirectorCEO
Transactions
  • Award

    Common Stock

    2017-04-19+1,0861,086 total
  • Award

    Options

    2017-04-19+216,580216,580 total
    Exercise: $12.44Exp: 2025-09-25Common Stock (216,580 underlying)
Footnotes (3)
  • [F1]Received in exchange for 1,380 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
  • [F2]Received in connection with the Merger in exchange for an employee stock option to buy 275,000 shares of PLx Opco Inc. common stock for $9.80 per share.
  • [F3]The option is exercisable as to 108,290 shares as of the date hereof, and will become exercisable as to an additional 54,145 shares on each of January 1, 2018 and (subject to continued employment through such date) January 1, 2019.

Documents

1 file
  • 4
    v464778_4.xmlPrimary

    OWNERSHIP DOCUMENT